PAA (ASX) PAA, A New Dawn , FDA ODD Approval and Entering Phase II MND Trial

Originally posted by theoc: ↑

"................ Someone said we didn’t really get the benefit out of ODD. I actually disagree because we would have slid further,............"

Howdy AD.Agree with the bulk of your content and do not have any beef with the new BoD in regards the work they are likely doing to get this train back on track. As to your comment above suspect you may have been channeling me and if so please forgive me for disagreeing with your disagreeing.
What I actually stated was the following ...

"............ Normally one would expect the granting of ODD would do a lot of that heavy lifting but in this case understandable that did not immediately occur..........." (lot of negative news at the same time).

The point of my contention is there was and still is a real need for the BoD to recognize this as not just a scientific project that need sorting but also includes a significant requirement to settle the natives and bring them/us along on the journey. The psychology aspect of this project and the recent activity is anathema to creating or maintaining market confidence. If this new BoD does not appreciate that point then why did we all shout and yell for change - we already had that process with the previous BoD ! In that regard I do not believe you and I are that far apart. How long would it take the new Chair to put out a positive statement and recognize the ample points you raise as being among the news items to come - then set about ticking them off accordingly !

Said it to the previous BoD and say it again now to the new. Do not climb carefully over all the big rocks only to carelessly trip on the pebbles. This whole project has remarkable upside however it is not in the hands of a private company that can go about the task as and when it pleases.. The only way to continuously bring the (public) market with you and live up to the statement of generating & providing shareholder value is to maintain clear communications that demonstrate you have the market interests in your central scope of vision.

Expand

Hey @theoc,

I can't help but think @adreamer might have been talking about me, I can't be sure, but I don't think there is any need to do any more disagreeing.

I will say I do agree with @adreamer now, upon reflection.

Havelots

Originally posted by adreamer: ↑

The options are almost endless, Nick.I would be happy for pretty much anything that isn't a statutory statement.

trial readiness AU
trial rollout timeline
trial arrangements in EU and/or USA
leadership structure
OLE all onboard
OLE onboarding results
Funding preps or arrangement
Chairman’s / new board’s observations
Webinar to meet the new board
addition to the board of “x” person with “y” skills
Any grants received (wishful thinking but…)
drug readiness
Any commercial achievements
confirmation of strategy
status of transfer to new arrangements from old board

I could keep going but I think you all have ideas.

Not that I think all or even half of the above is sorted, the mountains of work being done right now should have some gems to share.

It is a small team of mostly new, energetic, enthusiastic folks and without a handover so EVERYTHING will be a challenge. I think that the masses of retail investors are being very understanding but also, we are on that journey too and I have spoken to a lot of people who simply want confirmation that we have some safe hands working hard. The change is significant and so is their investment here.

Someone said we didn’t really get the benefit out of ODD. I actually disagree because we would have slid further, but I do also agree we can get more with confidence and clarity.

come on magic 8 ball, don’t let us down.

Expand

No.	Vol.	Price($)
11	537419	17.0¢

No.

Vol.

Price($)

537419

17.0¢

Price($)	Vol.	No.
18.0¢	140000	3

Price($)

Vol.

No.

18.0¢

140000

No.	Vol.	Price($)
11	537419	0.170
5	157060	0.165
9	476304	0.160
6	336734	0.155
8	225333	0.150

No.

Vol.

Price($)

537419

0.170

157060

0.165

476304

0.160

336734

0.155

225333

0.150

Price($)	Vol.	No.
0.180	140000	3
0.185	427553	5
0.190	720215	6
0.195	752882	12
0.200	297726	10

Price($)

Vol.

No.

0.180

140000

0.185

427553

0.190

720215

0.195

752882

0.200

297726

(20min delay)
Last 17.5¢		Change 0.000(0.00%)		Mkt cap ! $85.12M

Open	High	Low	Value	Volume
18.0¢	18.0¢	17.0¢	$141.2K	801.7K

Red Mountain Mining: record gold prices, two projects, two greenstone belts

Perseus Mining boosts stake in Predictive Discovery to 19.9% as latter's flagship project stalls

Laramide sniffs prime Kazakh uranium, with agreement over 6000 square km land position

Week 36 Wrap: AI hype wave tested again; Oz per capita recession continues; AirTrunk’s $40B+ payday

Shekel Brainweigh investor presentation webinar – the future of retail automation

As Nvidia cools, we're looking to Aussie AI

Metallurgical testing shows saleable copper and pyrite from QMines' Develin Creek project

Orthocell kicks off collagen-based dental bone repair product sales in Canada; eyeing next stop Brazil

HotCopper users blunt as Biotron sinks -35%; long-awaited COVID drug results same as placebo

CBA breaks trading record on strong day for Aussie financials

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News

Top Stories

Red Mountain Mining: record gold prices, two projects, two greenstone belts

Perseus Mining boosts stake in Predictive Discovery to 19.9% as latter's flagship project stalls

Laramide sniffs prime Kazakh uranium, with agreement over 6000 square km land position

Week 36 Wrap: AI hype wave tested again; Oz per capita recession continues; AirTrunk’s $40B+ payday

Shekel Brainweigh investor presentation webinar – the future of retail automation

As Nvidia cools, we're looking to Aussie AI

Metallurgical testing shows saleable copper and pyrite from QMines' Develin Creek project

Orthocell kicks off collagen-based dental bone repair product sales in Canada; eyeing next stop Brazil

HotCopper users blunt as Biotron sinks -35%; long-awaited COVID drug results same as placebo

CBA breaks trading record on strong day for Aussie financials

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News